{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05652335",
            "orgStudyIdInfo": {
                "id": "CR109234"
            },
            "secondaryIdInfos": [
                {
                    "id": "2022-001465-12",
                    "type": "EUDRACT_NUMBER"
                },
                {
                    "id": "79635322MMY1001",
                    "type": "OTHER",
                    "domain": "Janssen Research & Development, LLC"
                },
                {
                    "id": "2023-503679-12-00",
                    "type": "REGISTRY",
                    "domain": "EUCT number"
                }
            ],
            "organization": {
                "fullName": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis",
            "officialTitle": "Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-jnj-in-participants-with-relapsed-or-refractory-multiple-myeloma-or-previously-treated-amyloid-light-chain-al-amyloidosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04-18",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-04-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-07",
            "studyFirstSubmitQcDate": "2022-12-07",
            "studyFirstPostDateStruct": {
                "date": "2022-12-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\\[s\\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion)."
        },
        "conditionsModule": {
            "conditions": [
                "Relapsed or Refractory Multiple Myeloma",
                "Previously Treated Amyloid Light-chain (AL) Amyloidosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 195,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive JNJ-79635322. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified.",
                    "interventionNames": [
                        "Drug: JNJ-79635322"
                    ]
                },
                {
                    "label": "Part 2: Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive JNJ-79635322 at the RP2D regimen(s) determined in Part 1.",
                    "interventionNames": [
                        "Drug: JNJ-79635322"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "JNJ-79635322",
                    "description": "JNJ-79635322 will be administered as SC injection.",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation",
                        "Part 2: Dose Expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1: Number of Participants with Dose-limiting Toxicity (DLT)",
                    "description": "DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.",
                    "timeFrame": "Up to 2 years 5 months"
                },
                {
                    "measure": "Parts 1 and 2: Number of Participants with Adverse Events (AEs) by Severity",
                    "description": "An adverse event is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event.",
                    "timeFrame": "Up to 2 years 5 months"
                },
                {
                    "measure": "Part 2: Number of Participants with Abnormalities in Laboratory Values",
                    "description": "Number of participants with abnormalities in laboratory values (hematology and chemistry) will be reported.",
                    "timeFrame": "Up to 2 Years 5 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Serum Concentration of JNJ-79635322",
                    "description": "Serum samples will be analyzed to determine concentrations of JNJ-79635322.",
                    "timeFrame": "Up to 2 Years 5 months"
                },
                {
                    "measure": "Number of Participants with Presence of Anti-Drug Antibodies to JNJ-79635322",
                    "description": "Number of participants with presence of anti-drug antibodies to JNJ-79635322 will be reported.",
                    "timeFrame": "Up to 2 Years 5 months"
                },
                {
                    "measure": "Preliminary Anticancer Activity of JNJ-79635322 as Defined by International Myeloma Working Group (IMWG) 2016 Response Criteria",
                    "description": "Preliminary anticancer activity of JNJ-79635322 will be assessed according to the International Myeloma Working Group (IMWG) 2016 response criteria.",
                    "timeFrame": "Up to 2 Years 5 months"
                },
                {
                    "measure": "Time to Response (TTR) as Defined by IMWG 2016 Response Criteria",
                    "description": "TTR is defined as the time between date of first dose of study drug and the first efficacy evaluation at which the participant has met all criteria for partial response (PR) or better as defined by IMWG 2016 response criteria.",
                    "timeFrame": "Up to 2 Years 5 months"
                },
                {
                    "measure": "Duration of Response (DOR) as Defined by IMWG 2016 Response Criteria",
                    "description": "DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), per IMWG 2016 response criteria, or death due to any cause, whichever occurs first.",
                    "timeFrame": "Up to 2 Years 5 months"
                },
                {
                    "measure": "Part 2: Time to Response (TTR) as Defined by International Amyloidosis Consensus Criteria",
                    "description": "TTR is defined as the time between date of first dose of study drug and the first efficacy evaluation at which the participant has met all criteria for PR or better as defined by International Amyloidosis Consensus Criteria.",
                    "timeFrame": "Up to 2 Years 5 months"
                },
                {
                    "measure": "Part 2: Duration of Response (DOR) as Defined by International Amyloidosis Consensus Criteria",
                    "description": "DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), per International Amyloidosis Consensus Criteria or death due to any cause, whichever occurs first.",
                    "timeFrame": "Up to 2 Years 5 months"
                },
                {
                    "measure": "Part 2: Preliminary Anticancer Activity of JNJ-79635322 as Defined by International Amyloidosis Consensus Criteria",
                    "description": "Preliminary anticancer activity of JNJ-79635322 will be assessed according to the International Amyloidosis Consensus Criteria.",
                    "timeFrame": "Up to 2 Years 5 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nFor participants with relapsed or refractory multiple myeloma:\n\n* Have a documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria\n* Have relapsed or refractory disease, have been treated with a proteasome inhibitor, immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy for the treatment of multiple myeloma (MM), and should have been treated with at least 3 prior lines of therapy, or are refractory to proteosome inhibitor, IMiD agent, and an anti-CD38-based therapy regardless of prior lines of therapy\n* Must have an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1\n* Have measurable disease at screening as defined by at least 1 of the following: a) Serum M-protein level greater than or equal to (\\>=) 0.5 grams per deciliter (g/dL); or b) Urine M-protein level \\>=200 milligrams (mg)/24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) \\>=10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio; d) For participants without measurable disease in the serum, urine, or involved FLC, presence of 1 or more focus of extramedullary disease (EMD) which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion \\>=2 centimeter \\[cm\\] (at its greatest dimension) diameter on whole body Positron Emission Tomography and Computed Tomography (PET-CT) Scans (or whole body magnetic resonance imaging \\[MRI\\] approved by sponsor), and not previously radiated\n\nFor participants with previously treated AL amyloidosis:\n\n* Initial histopathological diagnosis of amyloidosis\n* Participant who is not a candidate for available AL amyloidosis therapy with established clinical benefit and should have received at least 3 cycles of 1 prior line of therapy or a total of at least 2 cycles of 2 or more prior lines of therapy for AL amyloidosis\n* Measurable disease at screening defined by at least 1 of the following: serum involved free light chain (iFLC) \\>=50mg/L or difference between involved and uninvolved free light chains (dFLC) \\>=50mg/L, or serum m-protein \\>= 0.5g/dL\n* One or more organs impacted by systemic AL amyloidosis\n* Left ventricular ejection fraction (LVEF) \\>=45%\n\nExclusion Criteria:\n\nFor participants with relapsed or refractory multiple myeloma:\n\n* Central Nervous System (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required\n* Active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary light chain amyloidosis\n* Received a cumulative dose of corticosteroids equivalent to greater than (\\>) 140 mg of prednisone within the 14-day period before the start of study treatment administration\n* Prior antitumor therapy within 21 days prior to the first dose of study treatment (proteasome inhibitor \\[PI\\] therapy or radiotherapy within 14 days, immunomodulatory drug (IMiD) agent therapy within 7 days, gene-modified adoptive cell therapy within 90 days, or CD3-redirecting therapy within 21 days)\n* Prior allogeneic transplant within 6 months before the start of study treatment administration or autologous transplant within 12 weeks before the start of study treatment administration\n* Live, attenuated vaccine within 4 weeks before the first dose of study treatment\n* Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (\\<=) 1 (except alopecia, tissue post-RT fibrosis \\[any grade\\] or peripheral neuropathy to Grade \\<=3)\n* The following medical conditions: pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation, human immunodeficiency (HIV) infection, active hepatitis B or C infection, stroke or seizure within 6 months prior to first dose of study treatment, autoimmune disease, serious active viral or bacterial infection, uncontrolled systemic fungal infection, cardiac conditions (myocardial infarction \\<=6 months prior to enrollment, New York Heart Association stage III or IV congestive heart failure, et cetera)\n\nFor participants with previously treated AL amyloidosis:\n\n* CNS involvement or clinical signs of meningeal involvement of AL amyloidosis. If either is suspected, whole brain MRI and lumbar cytology are required\n* Any form of non-AL amyloidosis, including but not limited to transthyretin (ATTR) amyloidosis\n* Active plasma cell leukemia, Waldenstrom's macroglobulinemia, or POEMS syndrome\n* Pulmonary compromise requiring supplemental oxygen use\n* Any serious medical conditions such as: active viral, bacterial, fungal infection; active autoimmune disease; HIV infection, active hepatitis B or C infection, stroke or seizure within 6 months prior to first dose of study treatment, significant cardiovascular conditions\n* Previous or current diagnosis of symptomatic multiple myeloma\n* Macroglossia that impairs swallowing difficulty\n* Received a cumulative dose of corticosteroids equivalent to \\> 140 mg of prednisone within the 14-day period before the start of study treatment administration\n* Prior antitumor therapy within 21 days prior to the first dose of study treatment (PI therapy or radiotherapy within 14 days, IMiD agent therapy within 7 days, gene-modified adoptive cell therapy within 90 days, or CD3-redirecting therapy within 21 days)\n* Prior allogeneic transplant within 6 months before the start of study treatment administration or autologous transplant within 12 weeks before the start of study treatment administration\n* Live, attenuated vaccine within 4 weeks before the first dose of study treatment\n* Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to \\<=1 (except alopecia, tissue post-RT fibrosis \\[any grade\\] or peripheral neuropathy to Grade \\<=3)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Contact",
                    "role": "CONTACT",
                    "phone": "844-434-4210",
                    "email": "Participate-In-This-Study@its.jnj.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Janssen Research & Development, LLC Clinical Trial",
                    "affiliation": "Janssen Research & Development, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "City of Hope Orange County Lennar Foundation Cancer Center",
                    "status": "RECRUITING",
                    "city": "Irvine",
                    "state": "California",
                    "zip": "92618",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.66946,
                        "lon": -117.82311
                    }
                },
                {
                    "facility": "University of California San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Colorado Blood Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Icahn School of Medicine at Mt. Sinai",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Levine Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28001",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "UZ Antwerpen",
                    "status": "RECRUITING",
                    "city": "Edegem",
                    "zip": "2650",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 51.15662,
                        "lon": 4.44504
                    }
                },
                {
                    "facility": "UZ Gent",
                    "status": "RECRUITING",
                    "city": "Gent",
                    "zip": "9000",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 51.05,
                        "lon": 3.71667
                    }
                },
                {
                    "facility": "CHU de Liege",
                    "status": "RECRUITING",
                    "city": "Liege",
                    "zip": "4000",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 50.63373,
                        "lon": 5.56749
                    }
                },
                {
                    "facility": "CHU Nantes",
                    "status": "RECRUITING",
                    "city": "Nantes",
                    "zip": "44093",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.21725,
                        "lon": -1.55336
                    }
                },
                {
                    "facility": "CHU Lyon Sud",
                    "status": "RECRUITING",
                    "city": "Pierre benite",
                    "zip": "69495",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.7009,
                        "lon": 4.82511
                    }
                },
                {
                    "facility": "Chu Rennes Hopital Pontchaillou",
                    "status": "RECRUITING",
                    "city": "Rennes",
                    "zip": "35000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.11198,
                        "lon": -1.67429
                    }
                },
                {
                    "facility": "Institut Claudius Regaud",
                    "status": "RECRUITING",
                    "city": "Toulouse",
                    "zip": "31100",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.60426,
                        "lon": 1.44367
                    }
                },
                {
                    "facility": "Osaka University Hospital",
                    "status": "RECRUITING",
                    "city": "Suita-shi",
                    "zip": "565-0871",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 34.76143,
                        "lon": 135.51567
                    }
                },
                {
                    "facility": "VUMC Amsterdam",
                    "status": "RECRUITING",
                    "city": "Amsterdam",
                    "zip": "1081 HV",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                },
                {
                    "facility": "UMC Utrecht",
                    "status": "RECRUITING",
                    "city": "Utrecht",
                    "zip": "3584 CX",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 52.09083,
                        "lon": 5.12222
                    }
                },
                {
                    "facility": "Hosp. Univ. Germans Trias I Pujol",
                    "status": "RECRUITING",
                    "city": "Badalona",
                    "zip": "08916",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.45004,
                        "lon": 2.24741
                    }
                },
                {
                    "facility": "Hosp Clinic de Barcelona",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08036",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hosp Univ Fund Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Clinica Univ. de Navarra",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "zip": "31008",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Hosp Clinico Univ de Salamanca",
                    "status": "RECRUITING",
                    "city": "Salamanca",
                    "zip": "37007",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.96882,
                        "lon": -5.66388
                    }
                },
                {
                    "facility": "University College Hospital",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "W1T 7HA",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "Royal Marsden Hospital",
                    "status": "RECRUITING",
                    "city": "Sutton",
                    "zip": "SM2 5PT",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.35,
                        "lon": -0.2
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",
            "url": "https://www.janssen.com/clinical-trials/transparency"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                },
                {
                    "id": "D000000686",
                    "term": "Amyloidosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000057165",
                    "term": "Proteostasis Deficiencies"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4021",
                    "name": "Amyloidosis",
                    "asFound": "Amyloidosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1483",
                    "name": "Immunoglobulin Light-chain Amyloidosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M28747",
                    "name": "Proteostasis Deficiencies",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T254",
                    "name": "AL Amyloidosis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}